Dupixent (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

26.09.2023 - If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat Of the approximately 21,000 children under the age ...

Related Keywords

Paris ,France General ,France ,Japan ,Georged Yancopoulos ,Regeneron Velocimmune ,Regeneron Velocimmunetechnology ,Exchange Commission ,Euronext ,Drug Administration ,Nasdaq ,Regeneron Pharmaceuticals Inc ,Dupilumab Development Program ,Regeneron Genetics Center ,Priority Review ,Biologics License Application ,Chief Scientific Officer George ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Regeneron Pharmaceuticals Chart ,Egeneron Pharmaceuticals Kurs ,Regeneron Pharmaceuticals Aktie ,